LINC01237: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

Target Name: LINC01237

NCBI ID: G101927289

LINC01237

Other Name(s): long intergenic non-protein coding RNA 1237 | Long intergenic non-protein coding RNA 1237

LINC01237: A Long Intergenic Non-Protein-Coding RNA as a Drug Target and Biomarker

LINC01237 is a long non-coding RNA (lncRNA) that has been identified in various organisms, including humans. It is characterized by its unique structure, which consists of a series of alternating exons derived from different genic regions. LINC01237 has been shown to play a crucial role in various cellular processes, including cell growth, differentiation, and disease development. As a result, it has gained significant interest as a potential drug target and biomarker.

Drug Target Potential

LINC01237 has been identified as a potential drug target due to its unique structure and various cellular processes that it is involved in. One of the key reasons for its potential as a drug target is its expression in various tissues and organs, which makes it an attractive target for small molecules. Additionally, its unique structure has allowed researchers to identify several potential drug targets that can interact with its protein product.

Biomarker Potential

LINC01237 has also been identified as a potential biomarker due to its involvement in various diseases. Its unique structure and various functions have allowed researchers to identify several biomarkers that can be used to diagnose and monitor disease progression. For example, LINC01237 has been shown to be involved in cancer development and has been used as a potential biomarker for several types of cancer, including neurobladder cancer, colorectal cancer, and breast cancer.

Expression and Functions

LINC01237 is a long non-coding RNA that has been shown to play a crucial role in various cellular processes. It is expressed in various tissues and organs and has been shown to be involved in cell growth, differentiation, and disease development. LINC01237 has been shown to interact with several proteins, including the protein tyrosine kinase (TKTK), which is involved in many cellular processes, including cell growth, differentiation, and disease development.

One of the key functions of LINC01237 is its role in cell growth and differentiation. It has been shown to be involved in the regulation of cell cycle progression and in the control of cell size. Additionally, LINC01237 has been shown to be involved in the regulation of stem cell maintenance and in the development of cancer.

Another function of LINC01237 is its role in disease development. Several studies have shown that LINC01237 is involved in the development of several diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, LINC01237 has been shown to be involved in the development of neurobladder cancer and has been used as a potential biomarker for this type of cancer.

Molecular Model and Targets

The molecular model of LINC01237 has been established using various bioinformatics tools. The structure of LINC01237 is characterized by a unique alternating exon pattern, where exons are derived from different genic regions. The exons are organized in a specific order, which is consistent with the function of the protein product.

Based on its unique structure and various functions, several potential drug targets have been identified for LINC01237. One of the key targets is the protein tyrosine kinase (TKTK), which is known to be involved in many cellular processes, including

Protein Name: Long Intergenic Non-protein Coding RNA 1237

The "LINC01237 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01237 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets